Catabodies Alzyme-Tauzyme For Alzheimer
US Market: Alzheimer disease treatment is an urgent problem (5.8 Mil patients).
Advantages: Competing antibodies failed because they induce the all-important inflammatory and vascular damage that compromises cognition. Intravenous and gene-delivered Alzyme destroyed and removed brain amyloid β without such off-target damage in mouse models. We also know how to cleanse the brain fully of both toxic amyloids (amyloid β, misfolded Tau) by combining Alzyme with a tau-directed catabody.
Investment Opportunity: Milestone-driven execution of Alzyme-Tauzyme development plan offers exit opportunities at increase valuation for investors with 3-4 years vision.